Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) announced its quarterly earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01, Bloomberg Earnings reports. Matinas BioPharma Holdings had a negative return on equity of 143.22% and a negative net margin of 8,834.65%.
Shares of Matinas BioPharma Holdings (NYSEAMERICAN MTNB) traded up $0.02 during midday trading on Friday, hitting $1.19. The stock had a trading volume of 66,584 shares, compared to its average volume of 348,032. Matinas BioPharma Holdings has a one year low of $1.01 and a one year high of $3.99.
COPYRIGHT VIOLATION NOTICE: “Matinas BioPharma Holdings Inc (MTNB) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://ledgergazette.com/2017/11/17/matinas-biopharma-holdings-inc-mtnb-posts-quarterly-earnings-results-beats-estimates-by-0-01-eps.html.
In other Matinas BioPharma Holdings news, Director Adam K. Stern acquired 100,000 shares of the company’s stock in a transaction that occurred on Friday, September 8th. The stock was bought at an average price of $1.38 per share, with a total value of $138,000.00. Following the completion of the purchase, the director now owns 793,992 shares of the company’s stock, valued at $1,095,708.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have purchased 110,000 shares of company stock valued at $151,250 in the last three months.
Several equities analysts have recently weighed in on the company. Roth Capital set a $9.00 price target on Matinas BioPharma Holdings and gave the company a “buy” rating in a research report on Thursday, August 10th. Maxim Group set a $6.00 price target on Matinas BioPharma Holdings and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, ValuEngine cut Matinas BioPharma Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th.
Matinas BioPharma Holdings Company Profile
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.